U.S. Pharmacist eNewsletter
April 2023

RSV in Older Adults Riskier Than Realized
A new model suggested that as many as 4.8 million symptomatic cases of respiratory syncytial virus (RSV) occur in the United States among patients aged 65 years and older. That burden is greater than previously recognized, according to another study, which looked at the U.S. and other high-income countries. Find out what a difference a vaccine could make.

Advertisement


Previous SARS-CoV-2 Infection Dampens Response to COVID-19 Vaccine
A previous case of SARS-Cov-2 might offer some protection against future COVID-19 infections, but it also appears to dampen the effect of the two-shot vaccine series in those patients. The problem is that prior infection can influence the T-cell response to vaccination, study authors advised in a recent report. Learn more about the results of this study.

Advertisement

CDC Recommends HBV Vaccination as Part of Screening Process
A one-time hepatitis B virus (HBV) screening of adults would be “complementary” to the 2022 Advisory Committee on Immunization Practices recommendation to vaccinate all adults aged 19 to 59 years for HBV infection, according to a new report. The CDC explains that screening establishes any history of infection, while vaccination protects from future infection and the need for additional testing. Read more.

Advertisement
Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App
Advertisement Advertisement